Platelet indices in Philadelphia-negative chronic myeloproliferative neoplasms / Indicii plachetari de volum în neoplasmele mieloproliferative cronice Philadelphia-negative

Open access

Abstract

Introduction: Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN): polycythemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF) are characterized by an increased rate of thrombosis complications partly due to platelets activation. Large platelets are more active, have an enhanced procoagulant function and have a pathogenic role in arterial and venous thrombosis. In our study we tried to establish if platelet volume indices (MPV, PDW, P-LCR) issued from automated complete blood count determination are significantly different in Ph-MPN patients in comparison to healthy subjects. Materials and methods: Blood cell counts including platelet volume indices were assessed for 102 Ph-MPN and 102 healthy subjects using the impedance method on Sysmex XS 1000i and glucose and lipid profile, were assessed on Architect c 8000. Assessement of JAK2V617 positivity was conducted with amplification refractory mutation system polymerase chain reaction (ARMS-PCR), in whole peripheral blood. Results: Platelet volume indices (PVI) measured with the impedance based method, did not show significant differences in Ph-MPN patients in comparison to healthy controls. We noticed a moderate correlation between these indices and the presence of JAK2V617F mutation. PVI were increased in the small subgroup of patients treated with anagrelide and decreased in patients treated with simvastatin, comparatively with untreated patients. Conclusion: In our study we did not find a significant difference between platelet volume indices from Ph-MPN patients and healthy subjects. Further studies are required to demonstrate correlations between platelet volume indices and JAK2 V617F mutation, treatment with anagrelide and statins, respectively

1. Vardiman JW, Brunning RD, Arber DA, Lebean MM, Porurt A, Telferi A, et al. Introduction and Overview of the Classification of the Myeloid Neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC, Lyon. 2008;18-49.

2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006 Dec;355(23):2452-66. DOI: 10.1056/NEJMra063728

3. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc HematolEduc Program. 2012 Dec;2012(1):571-81.

4. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis.Blood. 2013 Mar;122(13):2176-84. DOI: 10.1182/blood-2013-03-460154

5. Landolfi R, Di Gennaro I, Falanga A. Thrombosis in myeloproliferative disorders: pathogenic facts and speculation. Leukemia. 2008 Nov;22(11):2020-8. DOI: 10.1038/leu.2008.253

6. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with JAK2 mutation status. Haematologica. 2006 Feb;91(2):169-75.

7. Panova-Noeva M, Marchetti M, Russo L, Tartari CJ, Leuzzi A, Finazzi G, et al. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thromb Res. 2013 Jul;132(1):88-93. DOI: 10.1016/j. thromres.2013.05.003

8. Machin SJ, Briggs C. Mean platelet volume: a quick, easy determinant of thrombotic risk? J Thromb Haemost. 2010 Jan;8(1);146-7. DOI: 10.1111/j.1538-7836.2009.03673.x

9. Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, et al. Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res. 2011 Oct;128(4):358-60. DOI: 10.1016/j. thromres.2011.05.007

10. Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hämostaseologie. 2014 Feb;34(1):54-62. DOI: 10.5482/HAMO-13-10-0054

11. Leader A, Pereg D, Lishner M. Are platelet indices of clinical use? A multidisciplinary review. Ann Med. 2012 Dec;44(8):805-16. DOI: 10.3109/07853890.2011.653391

12. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta- analysis. J Thromb Haemost. 2010 Jan;8(1):148-56. DOI: 10.1111/j.1538-7836.2009.03584.x

13. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost. 2011 Jan;9(1):49-56. DOI: 10.1111/j.1538-7836.2010.04110.x

14. Muscari A, Puddu GM, Cenni A, Silvestri MG, Giuzio R, Rosati M, et al. Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thromb Res. 2009 Feb; 123(4):587-91. DOI: 10.1016/j. thromres.2008.03.025

15. Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost. 2010 Jan;8(1):157-62. DOI: 10.1111/j.1538-7836.2009.03498.x

16. Gohda F, Uchiumi H, Handa H, Matsushima T, Tsukamoto N, Morita K, et al. Identification of inherited macrothrombocytopenias based on mean platelet volume among patients diagnosed with idiopathic thrombocytopenia. Thromb Res. 2007;119(6):741-6. DOI: 10.1016/j.thromres.2006.06.011

17. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds.WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:35-38.

18. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005 Sep;106 (6):2162-68. DOI: 10.1182/ blood-2005-03-1320

19. Lippi G, Meschi T, Borghi L. Mean platelet volume increases with aging in a large population study. Thromb Res. 2012 Apr;129(4):e159-60. DOI: 10.1016/j.thromres. 2011.12.031

20. Zhang J, Huang W. Reference range of mean platelet volume in Chinese individuals. Thromb Res. 2014 Mar;133(3):517-8. DOI: 10.1016/j.thromres. 2013.12.011

21. Cho SY, Lee HJ, Lee WI, Suh JT, Park TS. Large population study for the reference range of mean platelet volume in Korean individuals. Thromb Res. 2012 Sep;130(3):557-8. DOI: 10.1016/j.thromres. 2012.05.009

22. Meisinger C, Prokisch H, Gieger C, Soranzo N, Mehta D, Rosskopf D, et al. A genome-wide association study indentifies three loci associated with mean platelet volume. Am J Hum Genet. 2009 Jan;84(1);66-71. DOI: 10.1016/j.ajhg.2008.11.015

23. Lancé MD, van Oerle R, Henskens YM, Marcus MA. Do we need time adjusted mean platelet volume measurements? Lab Hematol. 2010 Sep;16(3):28-31. DOI: 10.1532/LH96.10011

24. Vinholt JP, Hvas AM, Nybo M. An overview of platelet indices and methods for evaluation platelet function in thrombocytopenic patients. Eur J Haematol. 2014 Jun;92(5):367-76. DOI: 10.1111/ejh.12262

25. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Jou JM, Cervantes F. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 2012 Aug;23(5):336-43. DOI: 10.3109/09537104.2011.630112

26. Riedl J, Kaider A, Reitter EM, Marosi C, Jäger U, Schwarzinger I, et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Thromb Haemost. 2014 Apr;111(4):670-8. DOI: 10.1160/TH13-07-0603

27. Latger-Cannard V, Hoarau M, Salignac S, Baumgart P, Lecompte T, Nurden P. Mean platelet volume: comparison of three analysers towards standardization of platelet morphological phenotype. Int Jnl Lab Hem. 2012 Jun;34(3):300-10. DOI: 10.1111/j.1751-553X.2011.01396.x

28. Colita A, Butoianu E, Nicoara S. Boli clonale ale celulelor stem hematopoietice. In: Paun R. Tratat de Me dicina Interna, Hematologie, partea aIIa,Editura Medicala, Bucuresti. 1999;164-84.

29. Bain BJ, Disorders of red cells and platelets. In: Blood cells: A Practical Guide. 4th edition. Blackwell Publishing, Carlton, Victoria. 2006;283-97. DOI: 10.1002/9780470987551. ch8 DOI: 10.1002/9780470987551 DOI: 10.1002/9780470987551.ch9

30. Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger IS. Mean platelet volume reproductibility and association with platelet activity and anti-platelet therapy. Platelets. 2014;25(3):188-92. DOI: 10.3109/09537104.2013.793794

31. Panova-Noeva M, Marcetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, et al.Jak2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011 Sep;118(9):2599-601. DOI: 10.1182/blood-2011-02-339655

32. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide. Brit J Haematol 1999;104:886-892. DOI: 10.1046/j.1365-2141.1999.01234.x

33. Coban E, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hipolipidemic diet treatment. Platelets. 2008 Mar;19(2):111-4. DOI: 10.1080/09537100701230444

34. Carobbio A, Finazzi G, Anatonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009 Sep;37(9):1016-21. DOI: 10.1016/j. exphem.2009.06.006

35. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007 May;35(5):702-11. DOI: 10.1016/j.exphem.2007.01.053

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 96 96 12
PDF Downloads 35 35 1